NF-kappa B (NF-kB)

Subscribe to Selected New Research on NF-kappa B

8561 relevant articles (289 outcomes, 1022 trials/studies) found for this Bio-Agent

Description: Ubiquitous, inducible, nuclear transcriptional activator that binds to enhancer elements in many different cell types and is activated by pathogenic stimuli. The NF-kappa B complex is a heterodimer composed of two DNA-binding subunits: NF-kappa B1 and relA.

Also Known As:

NF-kB; NF-kappaB; Nuclear Factor kappa B; Ig-EBP-1; Enhancer-Binding Protein, Immunoglobulin; Factor NF-kB, Transcription; Ig EBP 1; Immunoglobulin Enhancer Binding Protein; NF kB; NF kappaB; NF-kB, Transcription Factor; Transcription Factor NF kB; Immunoglobulin Enhancer-Binding Protein; Transcription Factor NF-kB; kappa B Enhancer Binding Protein

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Umezawa, Kazuo: 19 articles (09/2008 - 04/2003)
2.	Aggarwal, Bharat B: 17 articles (07/2008 - 09/2002)
3.	Karin, Michael: 15 articles (02/2008 - 04/2002)
4.	Watanabe, Toshiki: 8 articles (05/2008 - 07/2004)
5.	Sarkar, Fazlul H: 8 articles (01/2008 - 07/2003)
6.	Horie, Ryouichi: 8 articles (09/2007 - 07/2004)
7.	Schmid, Roland M: 7 articles (09/2007 - 01/2002)
8.	Shishodia, Shishir: 7 articles (06/2007 - 08/2003)
9.	Christman, John W: 7 articles (05/2007 - 01/2003)
10.	Chiao, Paul J: 7 articles (02/2007 - 09/2002)

Related Diseases

1.	Neoplasms (Cancer) 01/01/2008 - "The inhibition of PC3 tumors by combined treatment correlated with significant reduction in expression of p-Akt and NF-kappaB in tumor tissue. " 01/01/2007 - "NF-kappaB plays a central role in the immune system and is described as a major actor in many of human cancers mainly because of its protective effects against apoptosis. " 08/01/1999 - "Thus, inhibiting NF-kappaB activation may sensitize cells to anticancer therapy, thereby providing a more effective treatment for certain cancers. " 11/01/2006 - "The results open new perspectives in the search for novel proapoptotic molecules effective in the treatment of cancers presenting aberrant NF-kappaB regulation." 10/30/2006 - "Since suppression of NF-kappaB has been shown to inhibit oncogenic potential of transformed cells, targeting it should be effective in the prevention and treatment of cancer." Order ALL the reference details at left...
2.	Inflammation 03/14/2005 - "CONCLUSION: NF-kappaB activation is an important event that may be involved in acute and chronic inflammation development and may contribute to self-protection against early inflammation damage. " 03/01/2009 - "Our findings project a role for p21 in the control of NF-kappaB-associated inflammation, and suggest that therapeutic modulation of p21 expression could be beneficial in inflammation-associated diseases." 03/21/2007 - "Thus, these stilbenoids were effective in inhibition of PGE2- or NO-mediated inflammation and NF-kappaB- or C/EBPdelta-mediated inflammatory gene expression. " 08/01/2005 - "Vectors, expressing inhibitors of signal transduction pathways involving to NF-kB and JAK-STAT-3, are effective in modulating joint inflammation in mice. " 05/15/2002 - "Thus, LXA(4) analog-mediated down-regulation of proinflammatory gene expression via inhibition of the NF-kappaB pathway can be therapeutic for diseases characterized by mucosal inflammation." Order ALL the reference details at left...
3.	Sepsis (Septicemia) 08/01/2009 - "CONCLUSION: While NF-kappaB inhibitors hold promise for inflammatory conditions such as sepsis, caution is necessary. " 12/15/2007 - "In conclusion, lymphocyte-directed augmentation of canonical NF-kappaB ameliorates immunosuppression during murine sepsis. " 04/01/2000 - "We postulated that early measurement of the activation of nuclear factor kappaB (NF-kappaB), a transcriptional regulatory protein involved in proinflammatory cytokine expression, may help to predict the outcome of sepsis. " 12/15/2007 - "In this study the function of canonical NF-kappaB in T cells was studied in the context of murine sepsis. " 08/01/2003 - "OBJECTIVE: The aim of the study is to explore the effect of NF-kappa B signal pathway in neonatal sepsis so as to provide the experimental base for corresponding clinical treatment of the sepsis, in which NF-kappa B is taken as the target. " Order ALL the reference details at left...
4.	Colitis 09/01/2006 - "CONCLUSIONS AND IMPLICATIONS: TFDG exerts protective effects in experimental colitis and inhibits production of inflammatory mediators through a mechanism that, at least in part, involves inhibition of NF-kappaB activation." 09/01/2007 - "The aim of the present study was to investigate whether the NF-kappaB essential modulator (NEMO)-binding domain (NBD) peptide, which has been shown to block the association of NEMO with the IkappaB kinasebeta subunit (IKKbeta) and inhibit NF-kappaB activity, reduces inflammatory injury in mice with colitis. " 05/15/2007 - "The aim of this study was to determine the in vivo role of TLR/NF-kappaB activation in a model of commensal bacteria-induced T cell-mediated colitis. " 02/01/2009 - "suntoryeus HY7801 can improve colitis via the inhibition of TLR-4-linked NF-kappaB activation." 02/01/2009 - "Lactobacillus suntoryeus inhibits pro-inflammatory cytokine expression and TLR-4-linked NF-kappaB activation in experimental colitis." Order ALL the reference details at left...
5.	Reperfusion Injury 12/01/2005 - "The use of MMF in concert with an agent that affects NF-kappaB activation may provide even further protection against lung reperfusion injury as multiple inflammatory pathways are inhibited." 06/01/2005 - "Nuclear factor {kappa}B inactivation in the rat liver ameliorates short term total warm ischaemia/reperfusion injury." 01/01/2007 - "The present study examined the role of hepatocyte NF-kappaB activation during ischemia-reperfusion injury. " 10/01/2002 - "CONCLUSION: The present study clearly demonstrates that enhanced MCP-1 expression in rat kidney during ischemia/reperfusion injury is mediated by NF-kappaB activation and oxidative stress. " 05/01/1997 - "This study constitutes the initial demonstration that H/R activates myocardial NF kappa B and induces adaptive signal transduction against ischemia-reperfusion injury." Order ALL the reference details at left...

Related Drugs and Biologics

1.	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
2.	Cytokines
3.	Transcription Factors (Transcription Factor)
4.	Transcription Factor AP-1 (Transcription Factor AP 1)
5.	DNA (Deoxyribonucleic Acid)
6.	NF-kappa B (NF-kB)
7.	Curcumin
8.	prolinedithiocarbamate (PDTC)
9.	Proteasome Endopeptidase Complex (Proteasome)
10.	NF-kappaB inhibitor alpha

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Transplants (Transplant)
3.	Resuscitation
4.	Immunotherapy
5.	Heterologous Transplantation (Xenotransplantation)

Best Treatments:
Research Summary Report
on Neoplasms

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 20112 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>